November 14th 2024
Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
November 14th 2024
The Business Case for Diversity
April 1st 2005For the third year in a row, Abbott Labs has made it into the top 10 companies judged by DiversityInc magazine to have the most diverse workforce. According to DiversityInc co-founder Luke Visconti, that makes Abbott, number five in the ranking, extraordinary. Merck is the only other pharma company to make the cut, but comes in at number 24, and is on a downturn-it was ranked 13 last year.
Is There Life After Big Pharma?
April 1st 2005You can have a biotech company with a great technology base, but if it doesn't have a product in Phase II development, Wall Street won't reward the company by increasing the value of its stock price. When products are valued over technology, there is a higher premium for commercially-focused business leaders.